Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, agosto 24
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Werewolf Therapeutics Inc
HOWL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.8833
0.0098
1.12%
al cierre: Aug 24, 5:00 PM EST
$0.8791
-0.0042
-0.48%
After hour: 4:59 PM EST
Get Report
Fusiones y adquisiciones:
Ambros Therapeutics, Inc announced it will be merged with Werewolf Therapeutics (HOWL) on Friday, August 21, 2026 for $47.5M paid in stock
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Werewolf Therapeutics Financials
Werewolf Therapeutics (HOWL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share
Benzinga Newsdesk
PRO
Werewolf Therapeutics Q1 EPS $(0.28), Inline
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For March 27, 2026
Benzinga Insights
PRO
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
Benzinga Newsdesk
PRO
Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 5.26 percent increase over losses of $(0.38) per share
Benzinga Newsdesk
PRO
Werewolf Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.36 percent. This is a 6.98 percent increase over losses of $(0.43) per share
Benzinga Newsdesk
Privacy Manager